Analysts Offer Predictions for LRMR Q1 Earnings

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Larimar Therapeutics in a report released on Tuesday, March 25th. HC Wainwright analyst E. White forecasts that the company will post earnings per share of ($0.43) for the quarter. HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Larimar Therapeutics’ Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.54) EPS and FY2027 earnings at ($1.57) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.16).

Several other research analysts have also commented on the company. Robert W. Baird cut their price objective on Larimar Therapeutics from $13.00 to $10.00 and set an “outperform” rating on the stock in a research report on Tuesday. Truist Financial assumed coverage on Larimar Therapeutics in a research report on Wednesday, January 29th. They set a “buy” rating and a $18.00 price target on the stock. Finally, Guggenheim reiterated a “buy” rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Larimar Therapeutics currently has an average rating of “Buy” and a consensus price target of $20.22.

Larimar Therapeutics Trading Up 1.3 %

Shares of LRMR stock opened at $2.31 on Wednesday. The company has a market cap of $147.39 million, a PE ratio of -2.01 and a beta of 0.99. The company’s fifty day simple moving average is $3.14 and its 200-day simple moving average is $5.20. Larimar Therapeutics has a 52 week low of $2.22 and a 52 week high of $11.20.

Institutional Trading of Larimar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP grew its position in shares of Larimar Therapeutics by 10.3% during the 4th quarter. Wellington Management Group LLP now owns 116,067 shares of the company’s stock valued at $449,000 after buying an additional 10,821 shares during the last quarter. Velan Capital Investment Management LP bought a new position in shares of Larimar Therapeutics during the fourth quarter valued at approximately $70,000. Sphera Funds Management LTD. raised its position in shares of Larimar Therapeutics by 9.9% during the 4th quarter. Sphera Funds Management LTD. now owns 455,604 shares of the company’s stock worth $1,763,000 after purchasing an additional 41,126 shares during the period. ProShare Advisors LLC bought a new stake in shares of Larimar Therapeutics in the 4th quarter worth approximately $58,000. Finally, Janus Henderson Group PLC boosted its position in Larimar Therapeutics by 15.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock valued at $24,936,000 after purchasing an additional 876,431 shares during the period. 91.92% of the stock is owned by institutional investors and hedge funds.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.